DecisionDx-SCC test predicts local recurrence and metastasis in high-risk cutaneous squamous cell carcinoma, enhancing personalized treatment decisions. The test categorizes patients into three risk ...

New, combined validation cohort of 1,412 patients with high-risk squamous cell carcinoma (SCC) demonstrates that the addition of DecisionDx-SCC to Brigham & Women's Hospital (BWH) staging ...

FRIENDSWOOD, Texas--(BUSINESS WIRE)--Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced new data demonstrating the ...

Study finds that DecisionDx-SCC adds clarity and confidence to risk-aligned treatment decisions, independent of clinicopathologic factors and staging Overall, these data demonstrate how DecisionDx-SCC ...

FRIENDSWOOD, Texas, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (CSTL), a company improving health through innovative tests that guide patient care, today announced the publication of ...

FRIENDSWOOD, Texas--(BUSINESS WIRE)--Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, will present new data on its gene expression ...

Radiologic imaging identified unexpected findings in nearly half of high-risk cutaneous squamous cell carcinoma (cSCC) cases, which led to changes in clinical management for 47%, in a retrospective ...

MADRID -- Treatment with cemiplimab (Libtayo) followed by surgery showed encouraging survival rates in patients with resectable stage II-IV cutaneous squamous cell carcinoma (SCC), according to follow ...

Randomized Phase III Study of Erlotinib Versus Observation in Patients With No Evidence of Disease Progression After First-Line Platin-Based Chemotherapy for Ovarian Carcinoma: A European Organisation ...

A retrospective study reports that the incidence of vulval SCC has remained stable over the past decade, but the diagnosis is delayed due to poor awareness and clinical presentation challenges.